Causeway Capital Management NVO trades
Sarah Ketterer
Sarah Ketterer Novo Nordisk A/S stake
total: 372
Trades details
- Total transactions:
- 5
- New positions:
- 1
- Added:
- 4
- Held since:
- 2025 Q2
- Held for:
- 5 quarters
- Latest activity:
- 2026 Q2
According to 2026 Q2 report, Sarah Ketterer holds 1,677,615 Novo Nordisk A/S (NVO) shares with a market value of roughly $80.42M accounting for 0.87% of the overall portfolio. To date, the estimated cost basis is nearly $53.25 for "buy" trades. Causeway Capital Management first purchased NVO in 2025 Q2, initially acquiring 353,884 shares. Since the initial investment in Novo Nordisk A/S (NVO), Causeway Capital Management has made 4 more transactions.
When did Sarah Ketterer buy Novo Nordisk A/S (NVO)?
Sarah Ketterer first invested in Novo Nordisk A/S (NVO) in 2025 Q2 at the reported quarter-end price of $69.02 per share.
What's the cost basis of Causeway Capital Management's NVO stake?
The estimated cost basis for Novo Nordisk A/S (NVO) stake is around $53.25 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $53.24
Sarah Ketterer's historical trades in Novo Nordisk A/S
5 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
0.87%
|
1,677,615
|
$47.94
|
$80,424,851
|
+42.87% (+503,402)
|
+0.26%
|
|
2026 Q1
|
0.53%
|
1,174,213
|
$36.75
|
$43,152,333
|
+18.15% (+180,363)
|
+0.08%
|
|
2025 Q4
|
0.70%
|
993,850
|
$50.88
|
$50,567,080
|
+42.80% (+297,871)
|
+0.21%
|
|
2025 Q3
|
0.51%
|
695,979
|
$55.49
|
$38,619,855
|
+96.67% (+342,095)
|
+0.25%
|
|
2025 Q2
|
0.39%
|
353,884
|
$69.02
|
$24,425,058
|
new
|
+0.39%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.